about
Interleukin-6 predicts short-term global functional decline in the oldest old: results from the BELFRAIL study.The glomerular filtration rate estimated by new and old equations as a predictor of important outcomes in elderly patients.Short-term prognostic value of forced expiratory volume in 1 second divided by height cubed in a prospective cohort of people 80 years and older.The clinical impact of valvular heart disease in a population-based cohort of subjects aged 80 and olderSignificance of serum immune markers in identification of global functional impairment in the oldest old: cross-sectional results from the BELFRAIL study.A framework provided an outline toward the proper evaluation of potential screening strategies.Prognostic value of circulating cytokines on overall survival and disease-free survival in cancer patients.CD4:8 Ratio Above 5 Is Associated With All-Cause Mortality in CMV-Seronegative Very Old Women: Results From the BELFRAIL Study.Prevalence and Prognostic Impact of Valve Area-Gradient Patterns in Patients ≥80 Years With Moderate-to-Severe Aortic Stenosis (from the Prospective BELFRAIL Study).Interleukin-6 as a first-rated serum inflammatory marker to predict mortality and hospitalization in the oldest old: A regression and CART approach in the BELFRAIL study.Multimorbidity measures were poor predictors of adverse events in patients aged ≥80 years: a prospective cohort study.General practitioners' judgement of chronic heart failure in the oldest old: Insights from the BELFRAIL study.No relation between CMV infection and mortality in the oldest old: results from the Belfrail study.CD4:8 ratio >5 is associated with a dominant naive T-cell phenotype and impaired physical functioning in CMV-seropositive very elderly people: results from the BELFRAIL study.Sputum cytokine mapping reveals an 'IL-5, IL-17A, IL-25-high' pattern associated with poorly controlled asthma.No relation between vitamin D status and physical performance in the oldest old: results from the Belfrail study.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.The impact of confounders on the test performance of natriuretic peptides for cardiac dysfunction in subjects aged 80 and older.The relationship between grip strength and muscle mass (MM), inflammatory biomarkers and physical performance in community-dwelling very old persons.Airflow limitation by the Global Lungs Initiative equations in a cohort of very old adults.Respiratory function and its predictive value for health related outcomes in the BELFRAIL cohort.Sputum “IL-5, IL-17A, IL-25-high” pattern is associated with uncontrolled asthma and worse lung functionMuscle Strength and Physical Performance as Predictors of Mortality, Hospitalization, and Disability in the Oldest OldHost transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIVWhole Blood Stimulation Assay as a Treatment Outcome Monitoring Tool for VL Patients in Ethiopia: A Pilot Evaluation
P50
Q34543951-C9E4C0DA-9CA2-400E-8846-F40F455C48B5Q35091993-09F0F094-3C33-4D61-A0A5-B085E295CCE2Q35132966-A75DEF5F-DE50-43F5-9B72-DA1E2C4E8434Q35891148-82689289-F357-4A9B-A4EB-62FFC75305D4Q37470982-824FB6E3-EFC1-4467-BD38-6D3BB272C1C5Q38080305-E2C68315-FAFB-43AC-BA82-34DE27CF2682Q38187451-6EB7D7EA-3DDB-4CC3-A5C1-BCB7420C1A86Q39121923-16970885-1F03-49FC-A970-8DE053A32169Q40685585-5F92A0E3-CD3B-418A-8FA3-0488429FEB69Q40860936-3287413D-419E-4901-8C82-0203E9339E7CQ41657931-22B9D0EF-1040-439F-9AA2-946A95B7AE6DQ41731992-EC6FC6D4-254A-4D45-99CE-B63F262B989FQ42206108-FDF395F7-578B-4FC9-833D-D42308A2D5C8Q42227108-A750B84A-BB2C-4B54-849B-0D33A5FCE1BFQ44487970-6592E5EA-CE0A-45F9-9EEC-85BD6B51D836Q45353188-EE3E2488-33EF-426E-A1EF-7D9F3B55421BQ47548487-D3DF3BD9-163F-49DE-B303-36139A27E8FEQ47616964-0FB75746-F868-4FE0-B1AF-910B90E6DA4CQ48373695-FA8FB1F6-6341-42B5-8662-B1F60710A3C5Q50856072-8934BEBB-2D85-4D8B-BD58-58A117F649CDQ50930003-7FC6D2C6-88A9-422E-8BB0-31E79EE65228Q54195717-193771A9-2381-472C-8BAD-529AFA95D9DCQ56482966-C9655848-5DD2-4599-95FE-80A96A8C2701Q58899559-34884825-3AA4-4819-AE2A-CA6F0304BBD9Q94495186-DE23E5F2-FFC8-442F-AD38-F86A1ED93DEBQ94596599-99142DBC-3213-451B-BB4D-84127155AEA1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wim Adriaensen
@ast
Wim Adriaensen
@en
Wim Adriaensen
@es
Wim Adriaensen
@nl
Wim Adriaensen
@sl
type
label
Wim Adriaensen
@ast
Wim Adriaensen
@en
Wim Adriaensen
@es
Wim Adriaensen
@nl
Wim Adriaensen
@sl
prefLabel
Wim Adriaensen
@ast
Wim Adriaensen
@en
Wim Adriaensen
@es
Wim Adriaensen
@nl
Wim Adriaensen
@sl
P106
P31
P496
0000-0002-9698-7449